Currently, the main way of Parkinson’s disease treatment is L-DOPA, which provides dopamine to the brain in order to overcome dopamine deficiency that occurs in Parkinson’s disease. In advanced stages of the disease, patients are affected with On-Off fluctuations (late motor complications), which can be overcome by a continuous delivery of L-DOPA.
To date, continuous delivery of L-DOPA is done by Duodopa, which is an invasive pump.
Lasting Effect has developed novel formulation intended for continues usage to enhance Dopamine release. The API is loaded into the tablet and released continuously in the oral cavity.
This drug combination is particularly suitable for buccal release as one component is well absorbed via the oral mucosa and the second component is well absorbed along the gastrointestinal tract.
The tablet with this drug combination can be used for the treatment of Parkinson’s disease side effects as well as for the treatment of Dementia and Alzheimer’s disease.
Trends and market size
Parkinson disease effect 1% of world population over 60 and 5% over 85.
Senior population in 2030 expected to reach 1.4 billion.
Neurology related market 26 billion USD, 2022. Global market growth 12.2% a year.
Parkinson side effect market 5.41 billion USD, 2022. Expected to reach 17.12 billion USD by 2033.
